Nanoparticulate drug delivery system of cyclosporine

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn , Issue 2, 2009, Pages 81-92

  Gupta, Manish K ^a   Mishra, Brahmeshwar ^a   Prakash, Deepak ^a   Rai, Santosh K ^a  

^a HCPG College   (India)

Author keywords

Cyclosporine; Eudragit nanoparticles; Nanoparticles; PVA (polyvinyl alcohol); Solvent evaporation method

Indexed keywords

CYCLOSPORIN; EUDRAGIT; NANOPARTICLE; POLYVINYL ALCOHOL;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; GRAFT REJECTION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; LUNG; MOUSE; NEPHROTOXICITY; NONHUMAN; PARTICLE SIZE; SOLVENT EVAPORATION TECHNIQUE; SPLEEN; STORAGE TEMPERATURE;

EID: 77953393013     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Khar RK, and Diwan M, "Targeted delivery of drugs", In; Jain, N.K., Ed., "Advances in Controlled and Novel Drug Delivery", First Edition 2001, CBS Publishers and Distributors, New Delhi, 2001; 452.
2. Jain S, Jain NK. Resealed erythrocytes as drug carriers. In: Jain NK, editor. Controlled and Novel Drug Delivery. New Delhi: CBS Publishers and Distributors; 2002. p. 256-7.
3. Tomilson E, "Site specific drug delivery using particulate systems", In; Banker, GS, Ed., "Modern Pharmaceutics", Second Edition, Revised and Expanded, Marcel Dekker, 1996, Inc., USA; 673.
4. Kreuter J, (1983), "Evaluation of nanoparticles as drug delivery systems, I. Preparation method", Pharm. Acta. Helv., 58; 156.
5. De Jaeghere F, Doelker E, and Gurny R, "Nanoparticles", In; Mathiowitz, E, Ed., "Encyclopaedia of controlled drug delivery", Vol.2, John Wiley and Sons, Inc., New York, USA, 1999, 641.
6. Susansmith MN. Immunological Aspects of Organ Transplantation: Isograft, Allograft, or Xenograft, 2002.
7. Ketel BL, Stuart FP. Immunobiology of Transplantation. In: Chatterjee SN, editor. Organ Transplantation. Bristol: John Wright and Sons (Printing) Ltd; 1982. p. 15-42.
8. Tripathi KD, editor. Essentials of Medical Pharmacology. 5th ed. New Delhi: Jaypee Brothers Medical Publishers(P) Ltd; 2003. p. 785-7.
9. Kompella UB, Bandi N, Ayalasomayajula SP. Poly(lactic acid) Nanoparticles for Sustained release of Budesonide. Drug Deliv Tech, 2001 Oct, 1(1):227-235.
10. Kim Y, Fluckiger L, Hoffman M, Idjouadiene IC, Atkinson J, Maincent P. The antihypertensive effect of orally administered nifedipine loaded nanoparticles in spontaneously hypertensive rats. Br J Pharmacol 1997;120:399-404.
11. Zengshuan MA, Yeoh H, Lim LY. Formulation PH modulates the interaction of insulin with chitosan nanoparticles. J Pharm Sci 2002;91:1404-11.
12. Pednekak DV, Singh KK. Particle size analysis- newer developments. Indian J Pharm Educ 2004;38(3):130-3.
13. Lee J. Drug nano- and microparticles proceed into solid dosage forms: Physical properties. J Pharm Sci. 2003;92 (10):2057-67.
14. Tiyaboanchal W, Woiszwillo J, Middaugh CR. Formulation and charactrization of Amphotericin B-Polyethylenimine-Dextran sulfate nanoparticles. J Pharm Sci 2002;91:1396-403.
15. Li LK, Wang N, Wu S. A novel biodegradable system based on gelatin nanoparticles and poly (lactic-co-glycolic acid) microspheres for protein and peptide drug delivery. J Pharm Sci. 1997;86(8):891-5.
16. Santhi K, Dhanraj SA, Ponnusankar S, Suresh B. Study on Formulation and Targeting Efficiency of Amphotericin B Nanospheres. Indian J Pharm Sci 2000(6):421-3.
17. Gosh MN, editor. Fundamentals of Experimental Pharmacology. 2nd ed. Calcutta: Scientific Book Agency; 1984. p. 154-5.
18. Kulkarni GT, Gowthamarajan K, Suresh B. Stability testing of pharmaceutical products: An overview. Indian J Pharm Educ. 2004;38(4):194-202.
19. Oliva A, Santovena A, Llabrews M, Farina JB. Stability study of human serum albumin pharmaceutical preparations. J Pharm Pharmacol. 1999;51:385-92.